Ronald van Marion - Concepedia

Author

Ronald van Marion

Erasmus MC ORCID

Also Known As

PALGA-group, R. Van Marion, R. van Marion, Ronald Van Marion, Ronald van Marion, Ronaldvan Marion

101

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Erasmus MC Cancer Institute Erasmus University Rotterdam Leiden University Medical Center University Medical Center Utrecht

About

Ronald van Marion is an author at Erasmus MC specializing in medicine, pathology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	19	1K
2	Health Sciences	5	5	298
3	Cell Biology	4	4	421
4	Engineering	2	2	30
5	Public Health	1	1	21

Ronald van Marion

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
<i>IDH1</i> and <i>IDH2</i> Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Clinical Cancer Research	2010	380
<i>TMPRSS2:ERG</i> Fusion by Translocation or Interstitial Deletion Is Highly Relevant in Androgen-Dependent Prostate Cancer, But Is Bypassed in Late-Stage Androgen Receptor–Negative Prostate Cancer Karin G. Hermans, Ronald van Marion, Herman van Dekken, Cancer Research Unique FusionUrologyFunctional GenomicsHighly RelevantGenetics	2006	239
<i>IDH1</i> mutations in low-grade astrocytomas predict survival but not response to temozolomide Hendrikus J. Dubbink, Walter Taal, Ronald van Marion, Neurology	2009	187
Verification and Unmasking of Widely Used Human Esophageal Adenocarcinoma Cell Lines Jurjen J. Boonstra, Ronald van Marion, David G. Beer, JNCI Journal of the National Cancer Institute	2010	128
IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study Yunlei Li, Jessica G. C. A. M. Buijs-Gladdines, Kirsten Canté-Barrett, PLoS Medicine	2016	102
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients Daan P. Hurkmans, Merian E. Kuipers, Jasper Smit, Cancer Immunology Immunotherapy	2020	100
Truncated ETV1, Fused to Novel Tissue-Specific Genes, and Full-Length ETV1 in Prostate Cancer Karin G. Hermans, Hetty A. van der Korput, Ronald van Marion, Cancer Research Prostate Cancer DevelopmentSystems BiologyNovel Tissue-specific GenesCancer GenomicsClinical Prostate Cancer	2008	97
Segregation of non-p.R132H mutations in<i>IDH1</i>in distinct molecular subtypes of glioma Lonneke A.M. Gravendeel, Nanne K. Kloosterhof, Linda B.C. Bralten, Human Mutation Tumor BiologyNeuro-oncologySomatic VariantGliomaTumor Heterogeneity	2010	96
High‐resolution array comparative genomic hybridization of chromosome arm 8q: Evaluation of genetic progression markers for prostate cancer Mark van Duin, Ronald van Marion, Kees J. Vissers, Genes Chromosomes and Cancer	2005	92
Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing Hendrikus J. Dubbink, Peggy N. Atmodimedjo, Ronald van Marion, Journal of Molecular Diagnostics Allelic VariantFunctional GenomicsSequencingMedicineGenetics	2016	74

Page 1